Evidence map›Paper›PMID 38486818›Full record

ArticleTherapeutic advances in gastroenterology2024

The synergy of dual faecal immunochemical and faecal calprotectin testing for accurate assessment of endoscopic and histological activity in inflammatory bowel disease.

Anuj Bohra, Nicholas Batt, Krishneel Dutt, Diana Lewis, Jonathan P Segal, Olga Newiadomski, Abhinav Vasudevan, Daniel R Van Langenberg

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Anuj BohraEastern Health Clinical School, Monash University, 8 Arnold Street, Box Hill, VIC 3128, Australia.ORCID https://orcid.org/0000-0003-2913-8225
Nicholas BattDepartment of Gastroenterology, Box Hill Hospital, Box Hill, VIC, Australia.
Krishneel DuttDepartment of Gastroenterology, Box Hill Hospital, Box Hill, VIC, Australia.
Diana LewisDepartment of Gastroenterology, Northern Hospital Epping, Epping, VIC, Australia.
Jonathan P SegalDepartment of Gastroenterology, The Royal Melbourne Hospital, Parkville, VIC, Australia.ORCID https://orcid.org/0000-0002-9668-0316
Olga NewiadomskiDepartment of Gastroenterology, Box Hill Hospital, Box Hill, VIC, Australia.
Abhinav VasudevanDepartment of Gastroenterology, Box Hill Hospital, Box Hill, VIC, Australia.
Daniel R Van LangenbergDepartment of Gastroenterology, Box Hill Hospital, Box Hill, VIC, Australia.
Box Hill Hospital · AUNorthern Hospital · AUThe Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Faecal biomarkers are increasingly utilized for disease assessment in inflammatory bowel disease (IBD). Objectives: To characterize the relative and combined accuracy of faecal calprotectin (FC) and faecal immunochemical testing (FIT) for detecting endoscopic and histologically active disease in Crohn's disease (CD) and ulcerative colitis (UC), subdivided by disease location. Design: A prospective cohort study. Methods: Patients with confirmed IBD undergoing routine ileocolonoscopy for activity assessment were prospectively recruited and performed both FC and FIT ±30 days of ileocolonoscopy. Endoscopic activity was assessed Results: In all, 137 (79 CD, 57 UC) patients were recruited. FC was more sensitive than FIT in detecting active endoscopic (CD: 91% Conclusion: FC demonstrated higher sensitivity and FIT higher specificity for active IBD. Hence, dual testing was synergistic, displaying excellent performance characteristics across most IBD locations and subtypes, holding promise for future clinical application. Trial registration: Not applicable.

Indexed as

disease activityfaecal biomarkersinflammatory bowel disease

Identifiers

PMID38486818
PMCPMC10938618
OpenAlexW4392752320

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.